公开(公告)号：US20100184665A1

公开(公告)日：2010-07-22

申请号：US12594210

申请日：2008-04-07

申请人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

发明人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

IPC分类号： A61K38/16 ,  C07K14/00 ,  C07H21/04 ,  A61K31/7088 ,  A61P3/10 ,  C12Q1/68

CPC分类号： G01N33/6893 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/47 ,  A61K45/06 ,  C12N9/2434 ,  C12N9/2445 ,  C12N2503/02 ,  C12Y302/01021 ,  C12Y302/01031 ,  G01N2333/50 ,  G01N2500/10 ,  G01N2800/044 ,  A61K2300/00

摘要： Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

摘要翻译： 使用βKlotho或增加或抑制βKlotho活性作为用于控制由FGF受体介导的FGF21的活性的药剂的物质，本发明提供包含这种βKlotho或这种物质作为活性成分的药物组合物，特别是用于 抗代谢综合征，特别是与控制血糖水平相关的治疗或预防用药物组合物。 此外，本发明提供了用于增强或抑制βKlotho活性的物质，FGF21样活性物质和βKlotho样活性物质的筛选系统，其使用已表达FGF受体的细胞系和/ 或其表面上的βKlotho。

公开(公告)号：US20100183733A1

公开(公告)日：2010-07-22

申请号：US12527693

申请日：2008-02-19

申请人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nazomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

发明人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nazomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

IPC分类号： A61K8/98 ,  C07K14/50 ,  A61K8/64 ,  A61Q9/04 ,  C12N15/63 ,  C12Q1/68

CPC分类号： C07K14/43536 ,  A61K8/64 ,  A61Q7/02 ,  G01N33/566 ,  G01N2333/50 ,  G01N2500/10

摘要： A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).

摘要翻译： 通过测定具有毛发生长抑制活性的内源性因子，筛选具有与内源因子相似的活性的物质或增强内源性因子的活性或表达的物质来提供脱毛剂或毛发生长抑制剂，以及 利用这些物质的生理活性。 已经发现FGF18抑制毛发生长。 公开了筛选FGF18样活性物质的方法，促进FGF18活性的物质或促进FGF18表达的物质，从​​而获得毛发生长抑制剂或脱毛剂的候选物。 还公开了一种毛发生长抑制剂或脱毛剂，其包含作为活性成分的FGF18和/或FGF18部分肽或FGF18样活性物质和/或促进FGF18活性或表达的物质（ 例如，Digenea单克隆提取物）。

公开(公告)号：US07589060B2

公开(公告)日：2009-09-15

申请号：US11662897

申请日：2005-09-08

申请人： Toru Imamura ,  Mitsuko Kawano ,  Akiko Kuramochi ,  Masashi Suzuki ,  Masahiro Asada

发明人： Toru Imamura ,  Mitsuko Kawano ,  Akiko Kuramochi ,  Masashi Suzuki ,  Masahiro Asada

IPC分类号： C07K14/50 ,  A61K38/18

CPC分类号： A61K38/1825 ,  A61K8/606 ,  A61K8/64 ,  A61K45/06 ,  A61K48/00 ,  A61Q7/00 ,  C07K14/50 ,  G01N33/5023 ,  G01N2333/50

摘要： It is intended to elucidate the effect of promoting hair follicle growth and to provide the following therapeutic agents for hair-related problems (1) to (3): (1) a hair growth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; (2) a hair regrowth promoting agent, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide; and (3) a therapeutic agent for alopecia, comprising as an active ingredient an expression vector incorporating a full-length FGF-18, a partial peptide thereof, or a cDNA encoding the full-length FGF-18 or the partial peptide.

摘要翻译： 旨在阐明促进毛囊生长的效果并提供以下用于毛发相关问题的治疗剂（1）至（3）：（1）毛发生长促进剂，其包含作为活性成分的表达载体，其包含 全长FGF-18，其部分肽或编码全长FGF-18或部分肽的cDNA; （2）一种毛发再生促进剂，其包含作为活性成分的包含全长FGF-18的表达载体，其部分肽或编码全长FGF-18或部分肽的cDNA; 包括作为活性成分的包含全长FGF-18，部分肽或编码全长FGF-18或部分肽的cDNA的表达载体作为活性成分。

公开(公告)号：US08697369B2

公开(公告)日：2014-04-15

申请号：US12594210

申请日：2008-04-07

申请人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

发明人： Masashi Suzuki ,  Toru Imamura ,  Yuriko Uehara ,  Kaori Motomura ,  Junko Oki ,  Syuichi Oka ,  Masahiro Asada ,  Akiko Kuramochi ,  Miho Kimura

IPC分类号： C12Q1/68

CPC分类号： G01N33/6893 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/47 ,  A61K45/06 ,  C12N9/2434 ,  C12N9/2445 ,  C12N2503/02 ,  C12Y302/01021 ,  C12Y302/01031 ,  G01N2333/50 ,  G01N2500/10 ,  G01N2800/044 ,  A61K2300/00

摘要： Using betaKlotho or a substance that increases or inhibits betaKlotho activity as an agent for controlling the activity of FGF21 mediated by an FGF receptor, the present invention provides a pharmaceutical composition comprising such betaKlotho or such substance as an active ingredient, particularly, a pharmaceutical composition for anti-metabolic syndrome, and further particularly, a pharmaceutical composition for therapeutic or preventive use associated with the control of blood glucose level. In addition, the present invention provides a screening system for each of a substance that enhances or suppresses betaKlotho activity, an FGF21-like active substance, and a betaKlotho-like active substance, which uses a cell system that has expressed an FGF receptor and/or betaKlotho on the surface thereof.

摘要翻译： 使用βKlotho或增加或抑制βKlotho活性作为用于控制由FGF受体介导的FGF21的活性的药剂的物质，本发明提供包含这种βKlotho或这种物质作为活性成分的药物组合物，特别是用于 抗代谢综合征，特别是与控制血糖水平相关的治疗或预防用药物组合物。 此外，本发明提供了用于增强或抑制βKlotho活性的物质，FGF21样活性物质和βKlotho样活性物质的筛选系统，其使用已表达FGF受体的细胞系和/ 或其表面上的βKlotho。

公开(公告)号：US20100286042A1

公开(公告)日：2010-11-11

申请号：US12682568

申请日：2008-10-10

申请人： Toru Imamura ,  Kaori Motomura ,  Akiko Kuramochi ,  Yoshiro Hanyu ,  Masashi Suzuki ,  Masahiro Asada ,  Akiko Hagiwara ,  Fumiaki Nakayama ,  Makoto Akashi

发明人： Toru Imamura ,  Kaori Motomura ,  Akiko Kuramochi ,  Yoshiro Hanyu ,  Masashi Suzuki ,  Masahiro Asada ,  Akiko Hagiwara ,  Fumiaki Nakayama ,  Makoto Akashi

IPC分类号： A61K38/18 ,  A61P17/02 ,  A61P43/00

CPC分类号： A61K38/1825 ,  C07K14/501 ,  C07K14/503 ,  C07K2319/00

摘要： There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.

摘要翻译： 提供了含有药物组合物的FGF2替代物，其包含作为活性成分的包含FGF1蛋白的氨基酸序列的嵌合蛋白，其中包含位置41序列中至少62-83位的序列的部分序列 -83被FGF2蛋白的氨基酸序列中相应位置的部分序列取代; 其余区由FGF1的氨基酸序列形成。 特别地，该药用组合物用于伤口愈合和用于预防和治疗辐射诱发的损伤，并且其表现出优于FGF2药物组合物的药理作用，此外，其可以容易地配制成制剂。

公开(公告)号：US20100203055A1

公开(公告)日：2010-08-12

申请号：US12527694

申请日：2008-02-19

申请人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nozomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

发明人： Toru Imamura ,  Miho Kimura ,  Mitsuko Kawano ,  Nozomi Tsujino ,  Akiko Kuramochi ,  Yuko Oda ,  Kaori Motomura ,  Masashi Suzuki ,  Masahiro Asada ,  Azusa Kameyama ,  Sumie Togayachi ,  Syuichi Oka

IPC分类号： A61K39/395 ,  A61K38/02 ,  A61K36/42 ,  A61K31/7088 ,  A61P17/14 ,  C12Q1/02

CPC分类号： A61K36/42 ,  A01K2227/105 ,  A61K8/64 ,  A61K8/97 ,  A61K31/7105 ,  A61K31/711 ,  A61K38/1825 ,  A61K45/06 ,  A61K2800/70 ,  A61Q7/00

摘要： It is intended to provide a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia by determining an endogenous factor that inhibits hair growth and screening for substances that inhibit the activity or expression of the endogenous factor. It has been found that FGF18 inhibits hair growth. A method of screening for substances that inhibit the activity of FGF18 or substances that inhibit the expression of FGF18 to thereby obtain candidates for the hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia is disclosed. Also disclosed is a hair growth promoting agent, hair regrowth promoting agent or therapeutic for alopecia comprising, as an active ingredient(s), a substance that inhibit the activity of FGF18 and/or a substance that inhibits the expression of FGF18 such as a partial peptide of FGF18 or a Momordica charantia hot water extract.

摘要翻译： 旨在通过测定抑制毛发生长的内源因子和筛选抑制内源性因子的活性或表达的物质来提供毛发生长促进剂，毛发再生促进剂或脱发治疗剂。 已经发现FGF18抑制毛发生长。 公开了筛选抑制FGF18活性的物质或抑制FGF18表达的物质从而获得毛发生长促进剂，毛发再生促进剂或脱发治疗剂的候选物的方法。 还公开了一种毛发生长促进剂，头发再生促进剂或脱发治疗剂，其包含作为活性成分的抑制FGF18活性的物质和/或抑制FGF18表达的物质，例如部分 FGF18肽或苦瓜热水提取物。

公开(公告)号：US20090286965A1

公开(公告)日：2009-11-19

申请号：US12159854

申请日：2007-01-09

申请人： Toru Imamura ,  Nozomi Tsujino ,  Masashi Suzuki ,  Masahiro Asada

发明人： Toru Imamura ,  Nozomi Tsujino ,  Masashi Suzuki ,  Masahiro Asada

IPC分类号： C07K14/50

CPC分类号： C07K14/50 ,  A61K8/64 ,  A61K38/00 ,  A61Q7/00

摘要： Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.

摘要翻译： 公开了具有改变的成纤维细胞生长因子受体特异性的突变蛋白，其通过从天然分泌的成纤维细胞生长因子18的氨基酸序列的N末端缺失一个或多个氨基酸残基而产生。蛋白突变体可以用于 用于调节毛发再生或生长的药物组合物或用于调节骨或软骨形成的药物组合物。

公开(公告)号：US07005415B1

公开(公告)日：2006-02-28

申请号：US09121017

申请日：1998-07-22

申请人： Toru Imamura ,  Masahiro Asada ,  Syuichi Oka ,  Masashi Suzuki ,  Atsuko Yoneda ,  Keiko Ota ,  Yuko Oda ,  Kazuko Miyakawa ,  Noriko Orikasa ,  Chie Asada ,  Tetsuhito Kojima

发明人： Toru Imamura ,  Masahiro Asada ,  Syuichi Oka ,  Masashi Suzuki ,  Atsuko Yoneda ,  Keiko Ota ,  Yuko Oda ,  Kazuko Miyakawa ,  Noriko Orikasa ,  Chie Asada ,  Tetsuhito Kojima

IPC分类号： A61K38/16 ,  A61K38/18 ,  C07K14/435 ,  C07K14/475

CPC分类号： C07K14/4723 ,  A61K38/1709

摘要： A heparin-binding protein functionalized by covalently bonding thereto a sugar chain, a method for producing the protein and a pharmaceutical composition containing the protein as an active ingredient, as well as a method for functionalizing a natural protein having no sugar chain by covalently bonding thereto a sugar chain.

摘要翻译： 通过与糖链共价键合的肝素结合蛋白质，该蛋白质的制造方法和含有该蛋白质作为活性成分的药物组合物，以及通过共价键合而使不含糖链的天然蛋白质官能化的方法 糖链。

公开(公告)号：US07893028B2

公开(公告)日：2011-02-22

申请号：US12159854

申请日：2007-01-09

申请人： Toru Imamura ,  Nozomi Tsujino ,  Masashi Suzuki ,  Masahiro Asada

发明人： Toru Imamura ,  Nozomi Tsujino ,  Masashi Suzuki ,  Masahiro Asada

IPC分类号： A61K38/18 ,  C07K14/50

CPC分类号： C07K14/50 ,  A61K8/64 ,  A61K38/00 ,  A61Q7/00

摘要： Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation.

摘要翻译： 公开了具有改变的成纤维细胞生长因子受体特异性的突变蛋白，其通过从天然分泌的成纤维细胞生长因子18的氨基酸序列的N末端缺失一个或多个氨基酸残基而产生。蛋白突变体可以用于 用于调节毛发再生或生长的药物组合物或用于调节骨或软骨形成的药物组合物。

公开(公告)号：US07741078B2

公开(公告)日：2010-06-22

申请号：US11547346

申请日：2005-03-31

申请人： Toru Imamura ,  Masahiro Asada ,  Masashi Suzuki

发明人： Toru Imamura ,  Masahiro Asada ,  Masashi Suzuki

IPC分类号： C12N15/12 ,  C12N1/00 ,  C12P21/02

CPC分类号： C07K14/501 ,  A61K38/00 ,  C07K2319/35

摘要： A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA. This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate. For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability. Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs. Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.

摘要翻译： 在其分子内具有共价键合的硫酸肝素糖链的肝素结合蛋白是通过将编码可以与硫酸肝素糖链修饰的肽选择性地编码到编码肝素结合蛋白的cDNA并在动物细胞中产生的cDNA来产生的 所得连接的cDNA的基因产物。 这种硫酸乙酰肝素糖链修饰的肝素结合蛋白通过共价键合含有少量硫酸软骨素的糖胺聚糖糖链来官能化。 例如，该肝素结合蛋白质的稳定性优异，例如耐热性，耐酸性，耐碱性和体内稳定性。 此外，硫酸乙酰肝素糖链修饰的肝素结合蛋白对细胞增殖和组织再生有效，具有调节FGFs生理功能的作用。 因此，该肝素结合蛋白作为预防或治疗各种FGF相关疾病的药物是非常有用的。